natgillin/translations-raw huggingface dataset:
After reconstitution, 1 mL of solution contains approximately 750 IU turoctocog alfa pegol.
Pärast manustamiskõlblikuks muutmist sisaldab 1 ml lahust ligikaudu 750 RÜ alfaturoktokogpegooli.
Attach the plunger rod and the syringe
Süstla ja kolvivarre kinnitamine
• Immediately connect the plunger rod to the syringe by turning it clockwise into the plunger inside the pre-filled syringe until resistance is felt.
Selleks keerake kolvivars kellaosuti suunas eeltäidetud süstla sees oleva kolvi sisse, kuni lõpuni.
Powder: 2000 IU turoctocog alfa pegol (approx. 500 IU/mL after reconstitution),
Pulber: 2000 RÜ alfaturoktokogpegooli (ligikaudu 500 RÜ/ml pärast manustamiskõlblikuks muutmist),
Syringe cap
• pitsitustunne rinnus
• Stop pushing the plunger rod and let it move back on its own while the reconstituted solution fills the syringe.
• Lõpetage surve kolvivarrele ja laske tal vabalt tagasi liikuda.
** Frequency is based on studies with all factor VIII products which included patients with severe haemophilia A. *** Preferred terms included in injection site reactions: Injection site reaction, Vessel puncture site haematoma, Infusion site reaction, Injection site erythema, Injection site rash, Vessel puncture site pain, and Injection site swelling.
*** Eelisterminid süstekoha reaktsioonidele: Süstekoha reaktsioonid, veeni punktsioonikoha hematoomid, infusioonikoha reaktsioonid, süstekoha erüteem, lööve süstekohal, valu veeni punktsioonikohas ja süstekoha turse.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the users and would normally not be recommended for longer than 4 hours stored at room temperature (up to 30°C) or 24 hours in a refrigerator (2°C - 8°C), unless reconstitution has taken place in controlled and validated aseptic conditions.
Ravimit võib säilitada 4 tundi toatemperatuuril (kuni 30 °C) või kuni 24 tundi külmkapis (2...8 °C), välja arvatud juhul, kui manustamiskõlblikuks muutmine on toimunud kontrollitud ja valideeritud aseptilistes tingimustes.
After reconstitution, 1 mL of solution contains approximately 250 IU turoctocog alfa pegol.
Pärast manustamiskõlblikuks muutmist sisaldab 1 ml lahust ligikaudu 250 RÜ alfaturoktokogpegooli.
Contents
KÕLBLIKKUSAEG
How Esperoct is given
Kuidas Esperoct'i manustatakse
Esperoct 2000 IU powder for solution for injection turoctocog alfa Pegol
Esperoct 2000 RÜ süstelahuse pulber turoctocogum alfa pegolum i.v.
Plunger
Kolvivars
Esperoct 2000 IU powder and solvent for solution for injection turoctocog alfa Pegol (recombinant coagulation factor VIII)
Esperoct 2000 RÜ süstelahuse pulber ja lahusti turoctocogum alfa pegolum (rekombinantne VIII hüübimisfaktor)
• Pull the plunger rod slightly downwards to draw the reconstituted solution into the syringe.
• Tõmmake kolvivart kergelt allapoole, et süstal täituks lahusega.
• Unscrew the vial adapter with the vial.
• Keerake viaali adapter viaali küljest lahti.
After reconstitution, 1 mL of solution contains approximately 500 IU turoctocog alfa pegol.
Pärast manustamiskõlblikuks muutmist sisaldab 1 ml lahust ligikaudu 500 RÜ alfaturoktokogpegooli.
Esperoct 3000 IU powder for solution for injection turoctocog alfa Pegol
Esperoct 3000 RÜ süstelahuse pulber turoctocogum alfa pegolum i.v.
Esperoct 3000 IU powder and solvent for solution for injection turoctocog alfa Pegol (recombinant coagulation factor VIII)
Esperoct 3000 RÜ süstelahuse pulber ja lahusti turoctocogum alfa pegolum (rekombinantne VIII hüübimisfaktor)
• Keep the plunger rod pushed completely in.
• Hoidke kolvivars lõpuni sees.
Esperoct 500 IU powder for solution for injection turoctocog alfa Pegol
Esperoct 500 RÜ süstelahuse pulber turoctocogum alfa pegolum i.v.
• chest tightness
• naha punetus (erüteem)
Esperoct 1500 IU powder and solvent for solution for injection turoctocog alfa Pegol (recombinant coagulation factor VIII)
Esperoct 1500 RÜ süstelahuse pulber ja lahusti turoctocogum alfa pegolum (rekombinantne VIII hüübimisfaktor)
Esperoct 1500 IU powder for solution for injection turoctocog alfa Pegol
Esperoct 1500 RÜ süstelahuse pulber turoctocogum alfa pegolum i.v.
Solvent
VIAAL
Esperoct 500 IU powder and solvent for solution for injection turoctocog alfa Pegol (recombinant coagulation factor VIII)
Esperoct 500 RÜ süstelahuse pulber ja lahusti turoctocogum alfa pegolum (rekombinantne VIII hüübimisfaktor)
(bromobutyl) and a rubber tip cap (bromobutyl) - 1 plunger rod (polypropylene).
- 1 kolvivars (polüpropüleen).
Esperoct 1000 IU powder for solution for injection turoctocog alfa Pegol
Esperoct 1000 RÜ süstelahuse pulber turoctocogum alfa pegolum i.v.
These may become severe and could be life-threatening, see
Need võivad süveneda ja muutuda eluohtlikuks, vt lisateavet peatükist „Allergilised reaktsioonid (ülitundlikkus)“
If the syringe cap is loose or missing, do not use the pre-filled syringe.
Ärge kasutage eeltäidetud süstalt, kui selle kate on lahti tulnud või puudub
Esperoct 1000 IU powder and solvent for solution for injection turoctocog alfa Pegol (recombinant coagulation factor VIII)
Esperoct 1000 RÜ süstelahuse pulber ja lahusti turoctocogum alfa pegolum (rekombinantne VIII hüübimisfaktor)
After reconstitution (after the powder has been mixed with the solvent): Once you have reconstituted Esperoct, it should be used immediately.
Pärast manustamiskõlblikuks muutmist (pärast pulbri lahustamist):
Esperoct is given as an injection into a vein (intravenously), see “Instructions on how to use Esperoct” for more information.
Lisateavet vaadake lõigust „Esperoct'i kasutusjuhend“.
Store the reconstituted product in the vial.
Manustamiskõlblikuks muudetud lahust tuleb säilitada viaalis.
Keep out of the sight and reach of children
Hoida laste eest varjatud ja kättesaamatus kohas.
For further information, see “Development of ‘FVIII inhibitors' (antibodies)” in section
Lisateavet vt jaotisest 2 „VIII faktori inhibiitorite (antikehade) teke“.
Catheter-related complications
Kateetrist tingitud tüsistused
Check with your doctor if you are not sure about how to use Esperoct.
Kui te ei ole kindel, kuidas Esperoct'i kasutada, pidage nõu oma arstiga.
This summary was last updated in 05-2011.
Kokkuvõtte viimane uuendus: 05-2011.
The European Commission granted a marketing authorisation valid throughout the European Union for Carbaglu to Orphan Europe on 24 January 2003.
Euroopa Komisjon andis Carbaglu müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Orphan Europe 24. jaanuaril 2003.
Other information about Carbaglu
Muu teave Carbaglu kohta
The summaries of opinion of the Committee for Orphan Medicinal Products for Carbaglu can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designations (NAGS deficiency: 18 October 2000; isovaleric acidaemia: 7 November 2008; methylmalonic acidaemia: 7 November 2008; propionic acidaemia: 7 November 2008).
Harvikravimite komitee arvamuse kokkuvõte Carbaglu kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designations (NAGS-i vaegus 18. oktoobril 2000; isovalerüül-atsideemia 7. novembril 2008; metüülmaloonatsideemia 7. novembril 2008; propioon-atsideemia 7. novembril.
The initial daily dose of Carbaglu should be 100 mg per kilogram body weight, but up to 250 mg/kg can be used if necessary.
Carbaglu algannus on 100 mg kehakaalu kg kohta ööpäevas, kuid vajaduse korral tohib kasutada ainult kuni 250 mg/kg.
‘Dispersible' means that the tablets can be dispersed (mixed) in water.
„Dispergeeruv” tähendab, et tablette võib segada veega.
The full EPAR for Carbaglu can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Euroopa avaliku hindamisaruande täistekst Carbaglu kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
The other eight patients were treated for hyperammonaemia of another cause.
Ülejäänud 8 patsiendil raviti muudest põhjustest tingitud hüperammoneemiat.
It is available as dispersible tablets.
Seda turustatakse dispergeeruvate tablettidena.
The company also presented information from the published literature on a further four patients treated with the active substance in Carbaglu.
Ettevõte esitas ka kirjanduses avaldatud teabe veel 4 patsienti kohta, keda raviti Carbaglu toimeainega.
In patients with NAGS deficiency, treatment may be started as early as the first day of life and the medicine is used for the patient's whole life.
NAGS-i vaegusega patsientidel võib ravi alustada esimesel elupäeval ja ravimit kasutatakse kogu elu.
The dose should then be adjusted to maintain normal blood ammonia levels.
Annust võib seejärel kohandada, et säilitada normaalne ammoniaagisisaldus veres.
The most common side effect with Carbaglu (seen in between 1 and 10 patients in 100) is increased sweating.
Carbaglu kõige sagedam kõrvalnäht (esinenud 1-10 patsiendil 100st) on liighigistamine.
For more information about treatment with Carbaglu, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Kui vajate Carbagluga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
They can easily be broken into two equal halves.
Tablette saab kergesti pooleks murda.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Carbaglu.
Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
In all of the studies, the main measure of effectiveness was the change in ammonia levels in the blood.
Kõikides uuringutes oli efektiivsuse põhinäitaja ammoniaagi sisaldus veres.
This is a summary of the European public assessment report (EPAR) for Carbaglu.
Käesolev dokument on ravimi Carbaglu Euroopa avaliku hindamisaruande kokkuvõte.
Carbaglu has been studied in 20 patients, 12 of whom had NAGS deficiency and were treated for an average of about three years.
Carbaglud uuriti 20 patsiendil, sh 12 NAGS-i vaegusega patsiendil, keda raviti keskmiselt ligikaudu 3 aastat.
• N-acetylglutamate synthase (NAGS) deficiency.
• N-atsetüülglutamaadi süntetaasi (NAGS) vaegus.
Because the number of patients with these diseases is low, they are considered ‘rare' and Carbaglu was designated an ‘orphan medicine' (a medicine used in rare diseases) on various dates (see below).
Et nende haigustega patsiente on vähe ja need haigused esinevad harva, nimetati Carbaglu eri haiguste jaoks eri kuupäevadel (vt allpool) harvikravimiks.
Carbaglu carglumic acid
Carbaglu kargluumhape
For the full list of side effects reported with Carbaglu, see the package leaflet.
Carbaglu kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
The CHMP concluded that Carbaglu was effective in reducing blood ammonia to normal levels and decided that Carbaglu's benefits are greater than its risks.
Inimravimite komitee järeldas, et Carbaglu oli efektiivne vere ammoniaagisisalduse normaliseerimisel ja otsustas, et Carbaglu kasulikkus on suurem, kui sellega kaasnevad riskid.
When ammonia builds up in the blood, it is toxic to the body, especially the brain.
Verre kogunenud ammoniaak on organismile, eriti ajule, mürgine.
Patients with this lifelong disease lack a liver enzyme called NAGS, which normally helps to break down ammonia.
Selle eluaegse haigusega patsientidel puudub maksaensüüm (N-atsetüülglutamaadi süntetaas NAGS), mis aitab tavaliselt kaasa ammoniaagi lagunemisele.
What is Carbaglu?
Mis on Carbaglu?
In patients with organic acidaemias, treatment is started when the patient has a hyperammonaemia crisis and continued until the crisis is finished.
Orgnaaniliste atsideemiatega patsientide ravi alustakse, kui patsiendil tekib hüperammoneemia ja jätkatakse kuni selle kadumiseni.
Why has Carbaglu been approved?
Miks Carbaglu heaks kiideti?
Carbaglu has also been studied in 57 patients (about two-thirds were newborn babies) with isovaleric acidaemia, methylmalonic acidaemia or propionic acidaemia who were treated with Carbaglu during hyperammonaemia crises.
Lisaks uuriti Carbaglud 57 (sh umbes 2/3 vastsündinuid) isovalerüül-atsideemia, metüülmaloonatsideemia ja propioon-atsideemiaga patsiendil, keda raviti Carbagluga hüperammoneemiakriisi ajal.
Carbaglu is very similar in structure to N-acetylglutamate, which activates an enzyme that breaks down ammonia.
Carbaglu on ehituselt väga sarnane N-atsetüülglutamaadile, mis aktiveerib ammoniaaki lagundavat ensüümi.
Patients on Carbaglu could be kept stable without a need for restrictions to the diet or the use of other medicines.
Carbaglud saavatel patsientidel saavutati stabiilsus ilma piiranguteta nende toitumises ja ilma teiste ravimiteta.
Carbaglu therefore helps break down ammonia, reducing ammonia blood levels and its toxic effects.
Seega aitab Carbaglu lagundada ammoniaaki ja vähendab ammoniaagi kontsentratsiooni veres ning vähendab mürgist toimet.
Carbaglu should not be used in people who may be hypersensitive (allergic) to carglumic acid or any of the other ingredients.
Carbaglud ei tohi kasutada patsiendid, kes võivad olla kargluumhappe või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
Carbaglu is used for the treatment of hyperammonaemia (high blood levels of ammonia) in patients with the following metabolic diseases:
Carbaglud kasutatakse hüperammoneemiaga (vere suur ammoniaagisisaldus) patsientide ravimiseks, kellel on järgmised ainevahetushaigused:
Carbaglu is a medicine that contains the active substance carglumic acid.
Carbaglu on ravim, mis sisaldab toimeainena kargluumhapet.
What is the risk associated with Carbaglu?
Mis riskid Carbagluga kaasnevad?
Carbaglu treatment should be started by a doctor who has experience in treating patients with metabolic diseases.
Carbaglu ravi tohib alustada üksnes ainevahetushaigustega patsientide ravis kogenud arst.
Carbaglu must not be used in women who are breastfeeding.
Carbaglud ei tohi kasutada rasedatel ja imetavatel naistel.
In patients with isovaleric acidaemia, methylmalonic acidaemia or propionic acidaemia, Carbaglu also induced a decrease in ammonia levels in the blood, following an average of 5.5 days of treatment.
Isovalerüül-atsideemia, metüülmaloon-atsideemia ja propioon-atsideemiaga patsientidel vähendas Carbaglu peale keskmiselt 5,5-päevast ravi ammoniaagi sisaldust veres.
In patients with NAGS deficiency, ammonia levels were brought back to normal after Carbaglu treatment.
NAGS-i vaegusega patsientidel saavutati Carbaglu ravi järel ammoniaagisisalduse normaliseerumine.
The tablets should be dispersed (mixed) in a small amount of water before being given to the patient.
Enne patsiendile manustamist tuleb tabletid segada väikese koguse veega.
How does Carbaglu work?
Kuidas Carbaglu toimib?
What benefit has Carbaglu shown during the studies?
Milles seisnes uuringute põhjal Carbaglu kasulikkus?
The Committee recommended that Carbaglu be given marketing authorisation.
Komitee soovitas anda ravimi müügiloa.
If the enzyme is not present,
Kui see ensüüm puudub, siis ammoniaak ei lagune ja koguneb verre.
What is Carbaglu used for?
Milleks Carbaglud kasutatakse?
• some organic acidaemias (isovaleric acidaemia, methylmalonic acidaemia and propionic acidaemia)
• Teatud orgaanilised atsideemiad (isovalerüül-atsideemia, metüülmaloon-atsideemia ja propioon atsideemia), kui patsientidel on valkude metabolismis osalevate teatud ensüümide vaegus.
How is Carbaglu used?
Kuidas Carbaglud kasutatakse?
How has Carbaglu been studied?
Kuidas Carbaglud uuriti?
It is available as tablets (60 mg).
Seda turustatakse tablettidena (60 mg).
This summary was last updated in 01-2015.
Kokkuvõtte viimane uuendus: 01-2015.
The full EPAR for Raloxifene Teva can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Euroopa avaliku hindamisaruande täistekst Raloxifene Teva kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The European Commission granted a marketing authorisation valid throughout the EU for Raloxifene Teva on 29 April 2010.
Euroopa Komisjon andis Raloxifene Teva müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 29. aprillil 2010.
Gradually, the bones become thin and fragile, and more likely to break (fracture).
Luud muutuvad järkjärgult urbsemaks ja hapramaks ning murduvad kergesti.
The recommended dose of Raloxifene Teva is one tablet taken once a day.
Raloxifene Teva soovitatav annus on üks tablett üks kord ööpäevas.
For more information about treatment with Raloxifene Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Kui vajate Raloxifene Tevaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Raloxifene Teva.
Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
The Committee recommended that Raloxifene Teva be given marketing authorisation.
Komitee soovitas anda Raloxifene Teva müügiloa.
Raloxifene has the same effect as oestrogen in the bone, but it does not have an effect in the breast or the womb.
Raloksifeenil on luudes samasugune toime kui östrogeenil, kuid ei mõju rinnanäärmetele ega emakale.
Other information about Raloxifene Teva
Muu teave Raloxifene Teva kohta
This is a summary of the European Public Assessment Report (EPAR) for Raloxifene Teva.
Käesolev dokument on ravimi Raloxifene Teva Euroopa avaliku hindamisaruande kokkuvõte.
Because Raloxifene Teva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Et Raloxifene Teva on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
This means that Raloxifene Teva is similar to a ‘reference medicine' already authorised in the European Union (EU) called Evista.
See tähendab, et Raloxifene Teva on sarnane võrdlusravimiga Evista, millel juba on Euroopa Liidus müügiluba.
Raloxifene Teva is a medicine that contains the active substance raloxifene hydrochloride.
Raloxifene Teva on ravim, mis sisaldab toimeainena raloksifeenvesinikkloriidi.
The CHMP concluded that, in accordance with EU requirements, Raloxifene Teva has been shown to have comparable quality and to be bioequivalent to Evista.
Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Raloxifene Teva võrdväärne kvaliteet ja bioekvivalentsus ravimiga Evista.
The active substance in Raloxifene Teva, raloxifene, is a selective oestrogen receptor modulator (SERM).
Raloxifene Teva toimeaine raloksifeen on selektiivne östrogeeni retseptori modulaator (SERM).
Raloxifene Teva is a ‘generic medicine'.
Raloxifene Teva on geneeriline ravim.
Raloxifene Teva raloxifene hydrochloride
Raloxifene Teva raloksifeenvesinikkloriid
Raloxifene Teva has been shown to significantly reduce vertebral fractures (breaks in the spine), but not hip fractures.
On tõendatud, et Raloxifene Teva vähendab oluliselt lülisambamurde, kuid mitte reieluukaelamurde.
Therefore, the CHMP's view was that, as for Evista, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Evista korral, ületab Raloxifene Teva kasulikkus sellega kaasnevad riskid.
What is Raloxifene Teva?
Mis on Raloxifene Teva?
Patients may also receive calcium and vitamin D supplements if they do not get enough from their diet. Raloxifene Teva is intended for long-term use.
Kui patsient ei saa toidust piisavalt kaltsiumi ja D-vitamiini, tuleb võtta neid täiendavalt.
Because Raloxifene Teva is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Evista.
Et Raloxifene Teva on geneeriline ravim, piirdusid patsiendiuuringud katsetega, milles näidati ravimi Raloxifene Teva bioekvivalentsust võrdlusravimiga Evista.
Why has Raloxifene Teva been approved?
Miks Raloxifene Teva heaks kiideti?
Raloxifene acts as an ‘agonist' of the oestrogen receptor (a substance that stimulates the receptor for oestrogen) in some tissues in the body.
Raloksifeen toimib mõnes organismi koes östrogeeni retseptori agonistina (stimuleerib östrogeeni retseptorit).
Raloxifene Teva is used for the treatment and prevention of osteoporosis (a disease that makes bones fragile) in women who have been through the menopause.
Raloxifene Tevat kasutatakse menopausijärgses eas naistel osteoporoosi (luu-urbnemuse) raviks ja ennetamiseks.
How has Raloxifene Teva been studied?
Kuidas Raloxifene Tevat uuriti?
What are the benefit and risk of Raloxifene Teva?
Milles seisneb Raloxifene Teva kasulikkus ja mis riskid ravimiga kaasnevad?
How is Raloxifene Teva used?
Kuidas Raloxifene Tevat kasutatakse?
What is Raloxifene Teva used for?
Milleks Raloxifene Tevat kasutatakse?
How does Raloxifene Teva work?
Kuidas Raloxifene Teva toimib?
The medicine can only be obtained with a prescription.
Raloxifene Teva on retseptiravim.
Please carefully follow the instructions of the veterinarian.
Palun järgige hoolikalt loomaarsti antud juhiseid.
Store in the original package in order to protect from light.
Hoida originaalpakendis, et kaitsta valguse eest.
If more than 50 broachings are required, the use of a draw-off needle is recommended.
Kui üle 50 korra läbistamine on vajalik soovitatakse kasutada draw-off nõela.
Povidone K30
Povidoon K30
10 tablets 20 tablets 100 tablets 500 tablets
10 tabletti 20 tabletti 100 tabletti 500 tabletti
A clinical response is normally seen within 3-4 days.
Tavaliselt ilmneb kliiniline vastus 3-4 päevaga.
Date of first authorisation: 10/02/2009 Date of last renewal: 23/01/2019
Esmase müügiloa väljastamise kuupäev: 10/02/2009 Müügiloa viimase uuendamise kuupäev: 23/01/2019
Acute respiratory infection.
Äge respiratoorne infektsioon.
Any unused half tablets may be returned to open blister and stored for up to 24 hours.
Kasutamata poolikuid tabletid võib panna tagasi avatud blistrisse ja hoiustada kuni 24 tundi.
Milk: 5 days
Piimale: 5 päeva.
Treatment of calves with Loxicom 20 minutes before dehorning reduces post-operative pain.
Vasikate ravi Loxicomiga 20 minutit enne sarvede eemaldamist vähendab operatsioonijärgset valu.
ATCvet code: QM01AC06
ATCvet kood: QM01AC06
The tablets can be broken into equal halves.
Tablette saab poolitada võrdseteks osadeks.
If skin and/or eye contact occurs, wash the affected parts immediately with water.
Nahale ja/või silma sattumisel loputage kahjustatud piirkondi kohe veega.
21 % of the recovered dose is eliminated in urine (2 % as unchanged meloxicam, 19 % as metabolites) and 79 % in the faeces (49 % as unchanged meloxicam, 30 % as metabolites).
21% manustatud annusest eritub uriiniga (2% muutumatul kujul meloksikaamina, 19% metaboliitidena) ja 79% väljaheitega (49% muutumatul kujul meloksikaamina, 30% metaboliitidena).
The tablets can be administered with or without food, are flavoured and are taken by most dogs voluntarily.
Tablette võib anda kas koos toiduga või ilma, need on maitsestatud ning enamik koeri võtavad neid vabatahtlikult.
BN {number}
Lot {number}
Maximal plasma concentrations are obtained after approximately 2 - 3 hours.
Maksimaalsed plasmakontsentratsioonid saavutatakse ligikaudu 2-3 tunni pärast.
CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER
PAKENDI SISU KAALU, MAHU VÕI ANNUSTE ARVU JÄRGI
A pale yellow homogenous paste.
Helekollane homogeenne pasta.
The metabolism in horses has not been investigated.
Metabolismi hobustel ei ole uuritud.
Co. Down, BT35 6PU United Kingdom
Co. Down, BT35 6PU Ühendkuningriik